Renagel Articles
Impax Labs settles with Genzyme over Renvela and Renagel generics
5 September 2012
Genzyme’s woes continue as it drops investigational APB follow-up for Renvela, after poor trial results
19 November 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
Genzyme's 2008 profit down on costs
23 February 2009
Genzyme's 3rd-qtr 2008 profit down 25%
3 November 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Genzyme's 1st-qtr revenues jump 25%
5 May 2008
Genzyme debuts Renvela for US dialysis patients
10 March 2008
Strong third quarter for Genzyme: GAAP net income reaches $159M on the back of good sales
5 November 2007
FDA approves Genzyme's Renvela
29 October 2007
Genzyme's 2nd-qtr net income jumps 4%
6 August 2007
Stock Commentary - New York week to June 4, 2007
11 June 2007
Stock Commentary - New York week to Jan 8, 2007
15 January 2007
Lower death rate with Genzyme
15 January 2007
Genzyme's 2nd-qtr 2006 revenue rises 19%
24 July 2006
Genzyme's 1st-qtr sales less than expected
1 May 2006
CORRECTION: Genzyme
22 August 2005
Lower death rate with long-term Renegal
8 August 2005
Stock Commentary - New York
8 August 2005
Genzyme guidance upped on good 2nd qtr
25 July 2005
Genzyme to buy Bone Care for $600M
16 May 2005
Genzyme's 1st-qtr revenues up 28%
25 April 2005
Nabi files for approval of PhosLo in EU
15 November 2004
UPDATE: Shire's Fosrenol faces delay for US approval
26 July 2004
Genzyme's 2nd-qtr revenues jump 58%
19 July 2004
Genzyme posts 1st-qtr net income of $67.9M
26 April 2004
Genzyme's revenues growth solid in 2003
30 November 2003
Genzyme swings to loss on acquisition costs
27 October 2003
Genzyme completes $600M SangStat deal
22 September 2003
Genzyme receives rare boost in 2nd qtr
21 July 2003
Tokyo pharma stocks - week to July 7
14 July 2003
Stock Commentary - Tokyo
14 July 2003
Roche to release a new drug each year in Japan
30 June 2003
Renagel sales boost Genzyme in 1st-qtr
28 April 2003
Stock Commentary - New York
28 April 2003
Stock Commentary - Tokyo
14 April 2003
Tokyo pharma stocks - week to April 7
14 April 2003
4th-qtr charges hit Genzyme General
17 March 2003
Shire's Fosrenol is approvable, says FDA
10 March 2003
Genzyme lowers guidance once again
24 February 2003
Altair unveils Renagel, Fosrenol rival
22 July 2002
Genzyme revenues up 12% in 2nd-qtr
22 July 2002
Genzyme General revises 2002 financial guidance
24 June 2002
Shire's Fosrenol clears bone safety hurdle
17 June 2002
Unspectacular quarter at Genzyme General
29 April 2002
Renagel sales leap at Genzyme General
18 March 2002
Genzyme's Renagel cleared in Brazil
16 August 2001
Stock Commentary - New York
5 July 2001
Genzyme expanding in Ireland and USA
31 May 2001
Genzyme 4th qtr net income rises 38%
9 March 2001
Genzyme investing $55 million in the UK
5 February 2001
Genzyme Corp set to acquire GelTex Pharmaceuticals for $1 billion
12 September 2000
Chugai shares downgraded on concerns over product pipeline
6 September 2000
New Genzyme Renagel plant in UK
26 April 2000
Genzyme's Renagel cleared in Europe
17 April 2000
Genzyme's Renagel cleared in Europe
14 April 2000
Genzyme General to focus on therapeutics
8 March 1999
Cholestagel filing planned for mid-year
12 January 1999
Renagel Approved In USA For End-Stage Renal Disease
4 November 1998
In Biotech Trust's Achievements In Fiscal 1997/98
3 November 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
RenaGel Filed In Europe
9 July 1998
Strong Revenue Growth At Genzyme General
11 March 1998
GelTex Taking The "Side" Out Of Drug Side Effects
2 February 1998
Clinical Trial News In Brief
20 January 1998
GelTex Files For Approval Of RenaGel
6 November 1997
GelTex' RenaGel Effective In Ph III
17 March 1997
Chugai Starts RenaGel Trials
9 December 1996
GelTex Awarded Patent
18 March 1996
CholestaGel Shows Promise
11 March 1996
Showing 1-82 of 82 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
